Costs averted | Chlamydia treatment (1,000 people) | Gonorrhea treatment (500 people) | Syphilis treatment (100 people) | HIV C&T (2,000 people) |
---|---|---|---|---|
Direct costs averted | Â | Â | Â | Â |
STI sequelae costs in treated people | $85,870 | $32,440 | $57,200 | $0 |
Congenital syphilis costs | $0 | $0 | $8,890 | $0 |
Population-level STI costs | $71,010 | $44,610 | $28,600 | $0 |
STI-attributable HIV costs | $34,120 | $10,860 | $74,010 | $0 |
HIV costs averted through C&T | $0 | $0 | $0 | $97,700 |
Indirect costs averted | Â | Â | Â | Â |
Indirect STI costs | $55,980 | $31,640 | $96,560 | $0 |
Indirect HIV costs | $142,960 | $45,490 | $310,100 | $409,390 |
Total costs averted | $389,950 | $165,030 | $575,360 | $507,100 |